Form 4: Blueprint Medicines Director Lynn Seely Receives Stock and Option Grants

Director Lynn Seely received stock and option grants from Blueprint Medicines Corp on June 12, 2024.

Summary

• On June 12, 2024, Lynn Seely, a director of Blueprint Medicines Corp, received a grant of 2,242 restricted stock units and an option to purchase 4,570 shares of common stock.
• The restricted stock units vest on the earlier of June 12, 2025, or the next annual meeting of the Issuer's stockholders.
• Each restricted stock unit represents a contingent right to receive one share of Blueprint Medicines' common stock.
• The option also vests on the earlier of June 12, 2025, or the next annual meeting of the Issuer's stockholders, and has an exercise price of $106.14.
• Following the transaction, Seely beneficially owns 13,254 shares of common stock and options to purchase 4,570 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral event with a slightly positive implication for long-term value.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages the director's continued service with the company.

Future Outlook

The vesting of the restricted stock units and stock options is contingent upon the earlier of June 12, 2025, or the next annual meeting of the Issuer's stockholders, suggesting continued alignment of the director's interests with the company's performance.

Industry Context

Stock and option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value and incentivizing long-term performance. This is a standard practice to attract and retain talent.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options and restricted stock units as part of their director compensation packages.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term value creation.

Stakeholder Impact

• Shareholders may view the stock and option grants positively as they align the director's interests with the company's long-term success.
• Employees may see this as a sign of stability and commitment from the company's leadership.

Key Dates